Global Leading Market Research Publisher QYResearch announces the release of its latest report “DON Immunochromatography Affinity Columns – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global DON Immunochromatography Affinity Columns market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for DON Immunochromatography Affinity Columns was estimated to be worth approximately US215millionin2025andisprojectedtoreachUS215millionin2025andisprojectedtoreachUS 335 million by 2032, growing at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2032. Deoxynivalenol (DON) , commonly known as vomitoxin, is a mycotoxin produced primarily by Fusarium graminearum and Fusarium culmorum. It frequently contaminates cereal grains including wheat, barley, oats, and corn, posing significant risks to both human and animal health—particularly swine, which experience feed refusal, vomiting, and immune suppression even at low parts-per-million (ppm) concentrations. Unlike conventional solid-phase extraction methods, DON immunoaffinity columns offer high specificity, minimal matrix interference, and superior recovery rates, making them the gold standard for regulatory compliance and routine quality control across the grain processing and animal feed industries.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984876/don-immunochromatography-affinity-columns
1. Market Overview: Addressing the Pain Point of DON Contamination
The core pain point driving the DON Immunochromatography Affinity Columns market is the increasing frequency and severity of Fusarium head blight (FHB) outbreaks, exacerbated by climate change—wetter growing seasons and temperature fluctuations. For grain elevators, feed mills, and food processors, rapid and reliable DON quantification is not optional; it is a regulatory and economic necessity. Contaminated shipments face rejection, downgrading, or mandatory detoxification, with losses often exceeding millions of dollars per incident. DON Immunochromatography Affinity Columns solve this by enabling sample cleanup and purification with recovery rates typically exceeding 85%, allowing downstream HPLC, LC-MS/MS, or ELISA-based detection to achieve limits of quantification as low as 0.1 ppm.
From an industry stratification perspective, a critical distinction exists between discrete manufacturing (e.g., batch testing of incoming grain lots at flour mills) and process manufacturing (continuous flow monitoring in large feed production lines). Discrete operations prioritize column-to-column consistency and ease of use for lab technicians, while process applications require faster flow rates, higher binding capacities, and compatibility with automated liquid handling systems.
2. Segmentation by Recovery Rate: A Unique Technical Differentiator
Unlike many immunoaffinity column markets segmented only by analyte or application, the DON Immunochromatography Affinity Columns market is uniquely segmented by recovery rate performance. This reflects the technical difficulty of achieving high and consistent DON purification across diverse sample matrices.
Segment by Type:
- 80% Below – Entry-level or older-generation columns. Still acceptable for preliminary screening but not for official regulatory methods. Represented ~18% of 2025 revenue.
- 80-90% – Workhorse segment for routine quality control. Accounts for approximately 42% of market share. Sufficient for most feed mill and grain elevator applications.
- 91-100% – High-performance segment. Required for official reference methods (AOAC, EU, Codex Alimentarius) and for laboratories serving export-oriented food manufacturers. Fastest-growing segment at 7.8% CAGR.
- 100% Above – Premium segment, typically indicating columns validated with spiked recovery exceeding 100% after matrix-matched calibration. Niche but essential for multi-toxin methods where DON is one of several analytes.
Exclusive observation (Global Info Research analysis): Recovery rate consistency (low batch-to-batch coefficient of variation) is emerging as a more critical purchasing criterion than absolute recovery percentage. Leading laboratories now demand columns with CV <5% across three consecutive lots—a technical barrier that only six global manufacturers currently meet.
3. Application Segmentation: Grains Dominate, Feed Accelerates
Segment by Application:
- Grains – Largest segment, accounting for ~58% of 2025 global revenue. Wheat and corn are primary matrices. The 2025 European wheat harvest experienced widespread DON contamination (EU Rapid Alert System for Food and Feed logged 147 DON-related notifications, up 34% from 2024), directly boosting column consumption.
- Feed – Fastest-growing application, projected CAGR of 7.2% 2026-2032. Swine feed is particularly sensitive; the US FDA advisory level for DON in swine feed is 1 ppm for grains destined for swine and 5 ppm for swine feed rations. A typical user case from Q4 2025: A Midwestern US feed cooperative processing 200,000 tons annually switched from SPE to DON immunoaffinity columns after a recall incident, reducing false positives by 62% and saving an estimated $1.2 million in avoided rejections.
- Others – Includes malted barley for brewing, oats for infant cereals, and corn-based ingredients for snack foods.
4. Competitive Landscape: Key Manufacturers
The market features a robust mix of global specialists and regional suppliers. Key players include:
Gold Standard Diagnostics Horsham, LCTech, Shimadzu, Biotez Berlin, PerkinElmer, VICAM, Ring Biotechnology, R-Biopharm AG, CHROMATIFIC, Neogen, Kwinbon Biotechnology, Shandong Meizheng Bio-Tech, Pribolab, Jiangsu Suwei Micro-Biology Research, Shandong Lvdu Bio-Sciences & Technology, Jiangsu Wisdom Engineering & Technology, BIOCOMMA, Beijing Nano-Ace Technology, Femdetection, Wuhan Huamei Wisherkon Biotech, Changsha Huaxue Biological Technology, Anavo, Shandong Vnya Bio-technology, Guanyibio, Prufunglab.
Recent technical development (December 2025): A leading European manufacturer launched a next-generation DON column incorporating monoclonal antibodies with enhanced cross-reactivity control against structurally similar trichothecenes (e.g., 3-AcDON, 15-AcDON), addressing a long-standing technical difficulty where acetylated DON variants caused overestimation errors.
Policy update (January 2026): China’s National Health Commission revised GB 2761-2025, lowering the maximum limit for DON in infant cereal-based foods from 200 µg/kg to 100 µg/kg. This has triggered increased IAC adoption among Chinese domestic processors and importers.
5. Regional Outlook
North America leads with ~36% market share, driven by intensive corn and wheat production and the FDA’s ongoing mycotoxin surveillance programs. Europe follows at ~31%, with Germany, France, and Poland as key demand hubs. Asia-Pacific is the fastest-growing region (CAGR 8.1%), propelled by China’s feed safety reforms and India’s expanding poultry sector.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
